Chondrosarcoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
However, a few published articles have been controversial regarding the association between <i>IDH1/IDH2</i> mutation status and clinical outcomes in chondrosarcomas.
|
31615936 |
2020 |
Chondrosarcoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Robust, persistent plasma 2-HG inhibition was observed in IDH1-mutant cholangiocarcinoma and chondrosarcoma.
|
31028664 |
2020 |
Chondrosarcoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Mutant IDH1-mediated modulation of SOX9 and CDKN1C expression regulated chondrosarcoma tumor progression, and DS-1001b upregulated the expression of these genes via a common mechanism involving the demethylation of H3K9me3.
|
31406254 |
2019 |
Chondrosarcoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
The low rate of IDH mutations observed in laryngotracheal chondrosarcomas suggests a different mode of tumorigenesis needing further exploration.
|
30296521 |
2019 |
Chondrosarcoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Targeting glutaminolysis in chondrosarcoma in context of the IDH1/2 mutation.
|
29576625 |
2018 |
Chondrosarcoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Mutations in isocitrate dehydrogenase 1 (IDH1) drive most low-grade gliomas and secondary glioblastomas and many chondrosarcomas and acute myeloid leukemia cases.
|
30249606 |
2018 |
Chondrosarcoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
IDH1/2 mutations occur in enchondromas and chondrosarcomas in patients with the non-hereditary enchondromatosis syndromes Ollier disease and Maffucci syndrome and in sporadic tumors.
|
29339836 |
2018 |
Chondrosarcoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
IDH1/2 Mutations Predict Shorter Survival in Chondrosarcoma.
|
29581779 |
2018 |
Chondrosarcoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
IDH1/2 mutations were detected in 87% (20/23) of dedifferentiated chondrosarcomas and 30% (6/20) of conventional chondrosarcomas.
|
28552826 |
2017 |
Chondrosarcoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Mutations in IDH1/2, present in more than 50% of primary conventional chondrosarcomas, make the development of IDH inhibitors a promising treatment option.
|
28133974 |
2017 |
Chondrosarcoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Recurrent mutations in IDH1 or IDH2 are prevalent in several cancers including glioma, acute myeloid leukemia (AML), cholangiocarcinoma and chondrosarcoma.
|
27355333 |
2016 |
Chondrosarcoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
A recent comprehensive study has identified the isocitrate dehydrogenase 1 (IDH1) and IDH2 mutations in conventional central and periosteal cartilaginous tumors, and it has subsequently been analyzed in intracranial chondrosarcoma and chondroma, including chondroma of the convexity dura mater.
|
27461824 |
2016 |
Chondrosarcoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Here, we identified the spectrum of IDH mutations in human enchondromas and chondrosarcomas and studied their effects in mice.
|
25730874 |
2015 |
Chondrosarcoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Specific point mutations in isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) occur in a variety of cancers, including acute myeloid leukemia (AML), low-grade gliomas, and chondrosarcomas.
|
25956465 |
2015 |
Chondrosarcoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Inhibition of mutant IDH1 decreases D-2-HG levels without affecting tumorigenic properties of chondrosarcoma cell lines.
|
25895133 |
2015 |
Chondrosarcoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Although the mutation frequency of IDH1 was low, we confirm the supposed relationship with central chondrosarcoma.
|
25648524 |
2015 |
Chondrosarcoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Isocitrate dehydrogenase 1 mutations (IDH1) and p16/CDKN2A copy number change in conventional chondrosarcomas.
|
25432631 |
2015 |
Chondrosarcoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
We sought to determine if treatment with AGI-5198 would similarly inhibit tumorigenic activity and D-2HG production in IDH1-mutant human chondrosarcoma cells.
|
26368816 |
2015 |
Chondrosarcoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Massively parallel paired-end sequencing of whole genomes of 10 primary chondrosarcomas revealed that the process of accumulation of somatic mutations is homogeneous irrespective of the pathological subtype or the presence of IDH1 mutations, is unique among a range of cancer types, and shares significant commonalities with that of prostate cancer.
|
25024164 |
2014 |
Chondrosarcoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
IDH1/2 mutation analysis appears to be a promising biomarker for the distinction of chondrosarcoma from chondroblastic osteosarcoma.
|
23598960 |
2013 |
Chondrosarcoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
More than 50% of patients with chondrosarcomas exhibit gain-of-function mutations in either isocitrate dehydrogenase 1 (IDH1) or IDH2.
|
24065766 |
2013 |
Chondrosarcoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Isocitrate dehydrogenase (IDH) genes 1 and 2 are frequently mutated in acute myeloid leukaemia (AML), low-grade glioma, cholangiocarcinoma (CC) and chondrosarcoma (CS).
|
23863747 |
2013 |
Chondrosarcoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Mutations in the metabolic enzymes isocitrate dehydrogenase 1 (IDH1) and 2 (IDH2) are frequently found in glioma, acute myeloid leukemia (AML), melanoma, thyroid cancer, and chondrosarcoma patients.
|
23954893 |
2013 |
Chondrosarcoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Our data suggest that the IDH1/2 mutation status could be valuable for distinguishing intracranial chondrosarcomas from chordomas.
|
22323113 |
2012 |
Chondrosarcoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Mutations were also found in 40% of solitary central cartilaginous tumors and in four chondrosarcoma cell lines, which will enable functional studies to assess the role of IDH1 and IDH2 mutations in tumor formation.
|
22057234 |
2011 |